http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101232872-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
| filingDate | 2010-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101232872-B1 |
| titleOfInvention | Pharmaceutical composition for the prevention and treatment of obesity comprising sphingosine-1-phosphate (ｓｐｈｉｎｇｏｓｉｎｅ-1 １ｈｏｓｐｈａｔｅ) or a pharmaceutically acceptable salt thereof as an active ingredient |
| abstract | The present invention relates to a pharmaceutical composition for preventing and treating obesity comprising sphingosine-1-phosphate or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the composition is sphingosine-1- By suppressing the expression of fat cell differentiation-related regulators through the phosphate 2 receptor, it significantly inhibits the differentiation of adipocytes and has the effect of inhibiting the accumulation of lipids, and thus can be usefully used as an effective medicine for preventing or treating obesity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10106797-B2 |
| priorityDate | 2010-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 179.